We have located links that may give you full text access.
Diarrheal etiology and impact of co-infections on rotavirus vaccine efficacy estimates in a clinical trial of a monovalent human-bovine (116E) oral rotavirus vaccine, Rotavac, India.
Clinical Infectious Diseases 2018 October 18
Background: Rotavirus vaccine (RV) efficacy estimates in low-resource settings are lower than in developed countries. We detected co-infections in cases of severe rotavirus diarrhea in a RV efficacy trial to determine whether these negatively impacted RV efficacy estimates.
Methods: We performed TaqMan Array Card assays for enteropathogens on stools from rotavirus EIA positive diarrhea episodes and all severe episodes (Vesikari score >= 11), from a phase III vaccine efficacy trial of Rotavac®, a monovalent human-bovine (116E) rotavirus vaccine, carried out across three sites in India. We estimated pathogen-specific etiologies of diarrhea, described associated clinical characteristics, and estimated the impact of co-infections on RV efficacy using the test-negative design.
Results: 1507 specimens from 1169 infants were tested for the presence of co-infections. Rotavirus was the leading cause of severe diarrhea even among vaccinated children, followed by adenovirus 40/41, Shigella/EIEC, norovirus GII, sapovirus, and Cryptosporidium spp. Bacterial co-infections in rotavirus positive diarrhea were associated with a longer duration of diarrhea and protozoal co-infections with increased odds of hospitalization. Using the test-negative design, RV efficacy against severe rotavirus gastroenteritis increased from 49.3% to 60.6% in the absence of co-infections (difference 11.3%; 95% CI: -10.3, 30.2).
Conclusion: While rotavirus was the dominant etiology of severe diarrhea, even in vaccinated children, a broad range of other etiologies was identified. Accounting for co-infections led to an 11.3% increase in the vaccine efficacy estimate. Although not statistically significant, an 11.3% decrease in vaccine efficacy due to presence of co-infections would explain an important fraction of the low RV efficacy in this setting.
Methods: We performed TaqMan Array Card assays for enteropathogens on stools from rotavirus EIA positive diarrhea episodes and all severe episodes (Vesikari score >= 11), from a phase III vaccine efficacy trial of Rotavac®, a monovalent human-bovine (116E) rotavirus vaccine, carried out across three sites in India. We estimated pathogen-specific etiologies of diarrhea, described associated clinical characteristics, and estimated the impact of co-infections on RV efficacy using the test-negative design.
Results: 1507 specimens from 1169 infants were tested for the presence of co-infections. Rotavirus was the leading cause of severe diarrhea even among vaccinated children, followed by adenovirus 40/41, Shigella/EIEC, norovirus GII, sapovirus, and Cryptosporidium spp. Bacterial co-infections in rotavirus positive diarrhea were associated with a longer duration of diarrhea and protozoal co-infections with increased odds of hospitalization. Using the test-negative design, RV efficacy against severe rotavirus gastroenteritis increased from 49.3% to 60.6% in the absence of co-infections (difference 11.3%; 95% CI: -10.3, 30.2).
Conclusion: While rotavirus was the dominant etiology of severe diarrhea, even in vaccinated children, a broad range of other etiologies was identified. Accounting for co-infections led to an 11.3% increase in the vaccine efficacy estimate. Although not statistically significant, an 11.3% decrease in vaccine efficacy due to presence of co-infections would explain an important fraction of the low RV efficacy in this setting.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app